

(19) World Intellectual Property  
Organization  
International Bureau



(10) International Publication Number  
**WO 2018/057808 A8**

(43) International Publication Date  
29 March 2018 (29.03.2018)

## (51) International Patent Classification:

<i>C07D 413/14</i> (2006.01)	<i>A61K 31/4155</i> (2006.01)
<i>A61K 31/4184</i> (2006.01)	<i>A61K 31/4178</i> (2006.01)
<i>A61K 31/4196</i> (2006.01)	<i>A61K 31/4245</i> (2006.01)
<i>A61K 31/4709</i> (2006.01)	<i>A61K 31/427</i> (2006.01)
<i>A61K 31/5375</i> (2006.01)	<i>A61K 31/433</i> (2006.01)
<i>C07D 413/04</i> (2006.01)	<i>A61K 31/444</i> (2006.01)
<i>A61P 29/00</i> (2006.01)	<i>A61K 31/497</i> (2006.01)
<i>A61P 35/00</i> (2006.01)	<i>A61K 31/501</i> (2006.01)
<i>C07D 405/14</i> (2006.01)	<i>A61K 31/506</i> (2006.01)
<i>A61K 31/341</i> (2006.01)	<i>C07D 409/14</i> (2006.01)
<i>A61K 31/4025</i> (2006.01)	<i>C07D 417/14</i> (2006.01)

## (21) International Application Number:

PCT/US2017/052817

## (22) International Filing Date:

21 September 2017 (21.09.2017)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

62/398,744 23 September 2016 (23.09.2016) US

(71) Applicant: **GILEAD SCIENCES, INC.** [US/US]; 333  
Lakerside Drive, Foster City, CA 94404 (US).


(72) Inventors: **CHANDRASEKHAR, Jayaraman**; C/o  
Gilead Sciences, Inc., 333 Lakerside Drive, Foster City,  
CA 94404 (US). **CODELLI, Julian, Andrew**; C/o Gilead  
Sciences, Inc., 333 Lakerside Drive, Foster City, CA 94404

(US). **NADUTHAMBI, Devan**; C/o Gilead Sciences, Inc.,  
333 Lakerside Drive, Foster City, CA 94404 (US). **PATEL,  
Leena**; C/o Gilead Sciences, Inc., 333 Lakerside Drive, Fos-  
ter City, CA 94404 (US). **PERREAULT, Stephane**; C/o  
Gilead Sciences, Inc., 333 Lakerside Drive, Foster City, CA  
94404 (US). **PHILLIPS, Gary**; C/o Gilead Sciences, Inc.,  
333 Lakerside Drive, Foster City, CA 94404 (US). **SEDIL-  
LO, Cassandra, F.**; C/o Gilead Sciences, Inc., 333 Lak-  
erside Drive, Foster City, CA 94404 (US). **TREIBERG,  
Jennifer, Anne**; C/o Gilead Sciences, Inc., 333 Lakerside  
Drive, Foster City, CA 94404 (US). **VAN VELDHUIZEN,  
Joshua**; C/o Gilead Sciences, Inc., 333 Lakerside Drive,  
Foster City, CA 94404 (US). **WATKINS, William, J.**; C/  
o Gilead Sciences, Inc., 333 Lakerside Drive, Foster City,  
CA 94404 (US).

(74) Agent: **REANEY, Shannon** et al.; Morrison & Foerster  
LLP, 755 Page Mill Road, Palo Alto, CA 94304-1018 (US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,  
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,  
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,  
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,  
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,  
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,  
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,  
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(54) Title: BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS



Formula I

Formula IA

(57) Abstract: The present application provides the compounds of formula I or IA or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein s, t, m, n, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup> and R<sup>7</sup> are as described herein. The compounds of formula I or IA selectively inhibit the activities of PI3K isoforms and are therefore useful in therapeutic treatments, in particular in the treatment of cancer and inflammatory conditions.

**(84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

**Published:**

- *with international search report (Art. 21(3))*

**(48) Date of publication of this corrected version:**

11 May 2018 (11.05.2018)

**(15) Information about Correction:**

see Notice of 11 May 2018 (11.05.2018)